CN112587729A - Bone repair material - Google Patents
Bone repair material Download PDFInfo
- Publication number
- CN112587729A CN112587729A CN202011545415.9A CN202011545415A CN112587729A CN 112587729 A CN112587729 A CN 112587729A CN 202011545415 A CN202011545415 A CN 202011545415A CN 112587729 A CN112587729 A CN 112587729A
- Authority
- CN
- China
- Prior art keywords
- bone
- particles
- repair material
- mass ratio
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 266
- 239000000463 material Substances 0.000 title claims abstract description 114
- 230000008439 repair process Effects 0.000 title claims abstract description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000008213 purified water Substances 0.000 claims abstract description 37
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000243 solution Substances 0.000 claims abstract description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000008215 water for injection Substances 0.000 claims abstract description 17
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002245 particle Substances 0.000 claims description 96
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 37
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 35
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 35
- 238000004140 cleaning Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 238000005406 washing Methods 0.000 claims description 18
- 241000283690 Bos taurus Species 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000002699 waste material Substances 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000012905 visible particle Substances 0.000 claims description 5
- 238000005238 degreasing Methods 0.000 claims description 4
- 230000003544 deproteinization Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 abstract description 5
- 238000007906 compression Methods 0.000 abstract description 5
- 230000000890 antigenic effect Effects 0.000 abstract description 4
- 238000003837 high-temperature calcination Methods 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 230000007547 defect Effects 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 40
- 241001465754 Metazoa Species 0.000 description 21
- 241000700159 Rattus Species 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 16
- 210000003625 skull Anatomy 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 9
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000011164 ossification Effects 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 230000037182 bone density Effects 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000001878 scanning electron micrograph Methods 0.000 description 6
- 241000282465 Canis Species 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000010478 bone regeneration Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004373 mandible Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001694 thigh bone Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 238000010041 electrostatic spinning Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The bone repair material provided by the invention adopts isopropanol and purified water to alternately clean and degrease, adopts hydrogen peroxide and ethylenediamine solution to jointly remove protein, and adopts purified water to repeatedly shake and clean, and water for injection to repeatedly turn and clean, so that antigenic substances are effectively removed, and the problems of poor compression resistance and reduced inductivity of the bone repair material caused by high-temperature calcination are simultaneously avoided.
Description
Technical Field
The invention belongs to the technical field of medical materials, and particularly relates to a bone repair material.
Background
The bone grafting operation has been applied to orthopedics clinic for many years, and autologous bone grafting is used as a gold standard for bone grafting and has a good healing effect clinically. The autogenous bone is mostly taken from fibula or hip bone of a patient, the bone taking amount is limited, the patient suffers from secondary operation, and the application of autogenous bone transplantation is limited.
In order to solve the problem of bone transplantation, artificial bone, allogeneic bone, xenogeneic bone and other materials are used for clinical treatment instead of autologous bone transplantation. Most of the artificial bone materials are hydroxyapatite crystals calcined at a high temperature of more than 1000 ℃ or beta-tricalcium phosphate or calcium sulfate crystals synthesized through chemical reaction, but the artificial bone materials cannot simulate the complex microstructure of natural bone materials, and a small amount of carbonate existing in the natural bone, especially in a weak crystal form, has important influence on the degradability of the bone. Therefore, the degradability of the artificial bone material is always a bottleneck restricting the clinical application of the artificial bone material.
The allogeneic bone is derived from human cadaver bone, and only fat and partial protein (mainly antigenic substances) need to be removed in the preparation process, and the bone is obtained by disinfection and sterilization. Because the protein is not completely removed, the compression resistance of the allogeneic bone is strong, the material has good histocompatibility with the human body, the immunological rejection is light after implantation, and the bone induction performance is relatively good. However, due to age differences among donors, the bone sources available for bone grafting are very limited, and allogeneic bones have a certain risk of viral infection.
The xenogenic bone is mostly bovine bone or pig bone, and has wide sources and good application prospect due to the similarity with the structure of human bone. The most representative bovine bone product is Bio-Os bone powder, which is the inorganic cancellous bone particles can be obtained by selecting the end of bovine femur, carrying out Soxhlet extraction and degreasing by toluene, carrying out deproteinization treatment by using an ethylenediamine solution, drying at 160 ℃, and then calcining at 350 ℃. As the calcining process is used, the hydroxyapatite in the Bio-Os bone powder is partially crystallized, so that the bone material has poor compressive resistance, is only suitable for bone defects of oral cavities, maxillofacial bones and other parts, and has no ideal clinical application for repairing bone defects with large defect parts and needing certain mechanical strength support.
The material causing immune reaction in fresh bone is mainly non-collagen and glycoprotein and fat on the surface of bone cell membrane. How to effectively destroy cell surface antigens and remove antigenic substances to obtain xenogenic bone materials with low immunogenicity is an important point in the preparation process of xenogenic bones. In the prior art, antigen removal methods mainly include deep low temperature freezing, chemical reagents (such as methanol/chloroform mixed solution), surfactants (SDS, Triton, etc.), protease treatment, high temperature calcination, and the like. The antigen and organic matter components can be completely removed by high-temperature calcination, but because the organic matter is completely removed, the bone material has poor compression resistance, only has osteoconductivity and loses inducibility, and cannot be applied to defect repair of orthopedics; however, the use of chemical reagents or enzymes for treatment of heterogeneous bones with high antigenicity cannot effectively remove antigens, and the risk of immunological rejection exists after the bone is implanted into the body.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a bone repair material, which removes non-collagen in allogeneic bone particles and glycoprotein and fat on the surface of a bone cell membrane, and can effectively maintain the compression resistance and the osteoconductivity of the bone repair material.
The purpose of the invention is realized by the following technical scheme:
on one hand, the bone repair material is prepared from bovine femoral particles and sodium hyaluronate gel, wherein the mass ratio of the bovine femoral particles to the sodium hyaluronate gel is 10 (5-7), and the mass ratio can be 10:5, 10:6 or 10:7, for example.
Preferably, the bovine femoral particles are defatted and deproteinized bovine femoral particles.
Preferably, the degreasing process comprises the following steps: and (3) repeatedly and alternately oscillating and cleaning the ox femoral bone particles for 3-6 times by using isopropanol and purified water to obtain the degreased ox femoral bone particles.
Preferably, the deproteinization process comprises the following steps:
1) adding the degreased bone particles into hydrogen peroxide, standing for 12-24h, removing the hydrogen peroxide, placing in purified water, shaking and cleaning for 3-6 times, drying at 75-100 ℃ for 5-7h, and sieving with a 14-mesh sieve to obtain sieved bone particles;
2) adding the sieved bone particles into an ethylenediamine solution, heating to slightly boil, keeping at the temperature of 100-125 ℃ for 7-9h, removing waste liquid, adding purified water, oscillating and cleaning for 3 times, and repeating the step twice;
3) washing the bone particles obtained in the step 2) with purified water for 15 times, washing with water for injection for 2 times, wherein the washing process is 3-6 min/time, turning over the container during the washing process, and discarding waste liquid to obtain deproteinized bone particles.
Preferably, the mass ratio of the animal bone particles to the isopropanol is 1 (2-3), such as 1:2,1: 2.5 or 1:3, and the mass ratio of the animal bone particles to the purified water is 1: 3.
preferably, in the step 1), the mass ratio of the defatted bone particles to the hydrogen peroxide is 1 (2-4), for example, 1:2,1:3,1: 4; the mass ratio of the degreased bone particles to the purified water is 1 (2-4), for example, 1:2,1:3, and 1: 4.
Preferably, the concentration of the ethylenediamine solution in step 2) is 70% to 100%, for example, 70%, 80%, 90%, 100%.
Preferably, the mass ratio of the sieved bone particles in the step 2) to the ethylenediamine solution is 1 (2-6), for example, 1:2,1:3,1:4, 1:5, and 1: 6.
Preferably, the mass ratio of the bone particles to the purified water in the step 3) is 1: 20; the mass ratio of the bone particles to the water for injection is 1: 20.
Preferably, the sodium hyaluronate gel concentration is 3% to 8%.
Preferably, the sodium hyaluronate gel is prepared by the following method: weighing 3-8 g of sodium hyaluronate, adding water for injection to 100g, stirring until the sodium hyaluronate is uniformly dispersed, sealing and standing at 2-8 ℃ for 3-16 h, and continuously stirring until the gel is transparent and has no visible particles.
Compared with the prior art, the invention has the following beneficial effects:
the bone repair material provided by the invention adopts isopropanol and purified water to alternately clean and degrease, adopts hydrogen peroxide and ethylenediamine solution to jointly remove protein, and adopts purified water to repeatedly shake and clean, and water for injection to repeatedly turn and clean, so that antigenic substances are effectively removed, and the problems of poor compression resistance and reduced inductivity of the bone repair material caused by high-temperature calcination are simultaneously avoided.
The bone repair material is a novel bone repair material which is formed by compounding inorganic bones prepared by removing organic matters from animal thighbones and a polysaccharide macromolecular carrier. The bone repair material has a three-dimensional reticular microscopic pore structure similar to a human bone, is beneficial to the formation and growth of new bones at an implanted position, and can partially change the structure of inorganic bones by osteoclasts and osteoblasts along with the repair of bone tissues. The polysaccharide macromolecular substance which is natural and biodegradable and has good biocompatibility and cell affinity is used as a carrier, so that the adhesion of inorganic bone particles and a defect part is enhanced, meanwhile, the macromolecular substance endows the material with good plasticity, the retention time of the material around an operation point is prolonged, and the operability of the bone repair material is improved. Along with the repair of bone tissues, the bone repair material is gradually degraded and absorbed in a human body, does not need to be taken out by a secondary operation, and has good biocompatibility.
Drawings
FIG. 1A is an SEM image of the product at 50 times magnification;
figure 1B is an SEM image of the product at 500 x magnification,
FIG. 2 is a Micro CT three-dimensional reconstruction map of a bone repair material prepared in example 1 of the present invention;
fig. 3A is a 50-fold SEM image of a bone repair material prepared in inventive example 1;
fig. 3B is a 5000-fold SEM image of the bone repair material prepared in inventive example 1;
FIG. 4 is a graph of the effect of different preparation methods on the compressive strength of a bone hemostatic material;
FIG. 5A is a graph showing the effect of the bone repair material at week 6 after the operation of the experimental group;
FIG. 5B is a graph showing the effect of the bone repair material at week 6 after the operation in the experimental group;
FIG. 5C is a graph showing the effect of the post-operative 6 th week bone repair material in the experimental group;
FIG. 5D is a graph showing the effect of the bone repair material at week 24 after the control group operation;
FIG. 6 is a view of Micro CT observation after 8 weeks of SD rat skull defect repair test;
FIG. 7 shows the detection result of the pixel CT value of the bone defect repair area of SD rat;
FIG. 8A is the HE staining observation experiment group bone regeneration status after 8 weeks of SD rat bone defect repair;
FIG. 8B is the HE staining observation control group bone regeneration status after 8 weeks of SD rat bone defect repair;
FIG. 9A is a photograph of an alveolar bone defect;
FIG. 9B is a photograph showing the filling of an alveolar bone defect with the bone repair material according to example 1 of the present invention;
fig. 10A shows the Masson trichrome staining results of the pathological section for canine alveolar bone filling repair in the experimental group;
fig. 10B is the results of Masson trichrome staining of a pathological section of canine alveolar bone filling repair in the control group;
FIG. 11A is a comparison of bone volume counts for experimental and control groups at week 8 post-surgery;
FIG. 11B is a comparison of trabecular bone thickness at week 8 post-surgery in experimental and control groups;
FIG. 12A is a photograph of histological observation of the experimental group;
FIG. 12B is a photograph showing histological observation of the control group;
FIG. 13A is a graph showing the adhesion of mesenchymal cells of SD rat bone marrow to the surface of the product in example 6;
FIG. 13B is a graph comparing the proliferation of mesenchymal cells on the present product and synthetic hydroxyapatite in example 6;
FIG. 14A is a graph of subcutaneous histological HE staining of SD rats 2 weeks after administration of the product;
FIG. 14B is a graph of subcutaneous histological HE staining of SD rats 4 weeks after administration of the product;
FIG. 14C is a graph of subcutaneous histological HE staining of SD rats 6 weeks after administration of the product;
FIG. 14D is a graph of subcutaneous histological HE staining of SD rats 8 weeks after administration of the product;
FIG. 14E is a graph of subcutaneous histological HE staining of SD rats 12 weeks after administration of the product.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Example 1
The embodiment provides a preparation method of a bone repair material, which comprises the following steps:
1) taking animal bone particles, and repeatedly and alternately oscillating and cleaning the animal bone particles for 3-6 times by using isopropanol and purified water to obtain degreased bone particles, wherein the mass ratio of the animal bone particles to the isopropanol is 1: 2.5;
2) adding the degreased bone particles into hydrogen peroxide, standing for 12-24h, removing the hydrogen peroxide, placing in purified water, shaking and cleaning for 3-6 times, drying at 75-100 ℃ for 5-7h, and sieving with a 14-mesh sieve to obtain sieved bone particles;
3) adding the sieved bone particles into 70-100% ethylenediamine solution, heating to slightly boil, keeping at the temperature of 100-125 ℃ for 7-9h, discarding the waste liquid, adding purified water, oscillating and cleaning for 3 times, and repeating the step 3) twice;
4) cleaning the bone particles obtained in the step 3) with purified water for 15 times, cleaning with water for injection for 2 times, wherein the cleaning process is 3-6 min/time, turning over the container during cleaning, and discarding waste liquid to obtain deproteinized bone particles;
5) and (3) uniformly mixing the sodium hyaluronate gel and the deproteinized bone particles according to the mass ratio of 10 (5-7), sealing, standing for 4-6min, and freeze-drying to obtain the bone repair material.
In some embodiments, the mass ratio of the sodium hyaluronate gel to the deproteinized bone particles is 10:5 or 10: 7.
In some embodiments, in step 1), the mass ratio of the animal bone particles to the isopropanol is 1:2 or 1:3, and the mass ratio of the animal bone particles to the purified water is 1: 3.
in some embodiments, in step 2), the mass ratio of the defatted bone particles to the hydrogen peroxide is 1 (2-4), for example, 1:2,1:3,1: 4; the mass ratio of the degreased bone particles to the purified water is 1 (2-4), for example, 1:2,1:3, and 1: 4.
In some embodiments, in step 3), the mass ratio of the sieved bone particles to the ethylenediamine solution is 1 (2-6), for example, 1:2,1:3,1:4, 1:5, and 1: 6.
In some embodiments, in step 4), the mass ratio of the bone particles to the purified water is 1: 20; the mass ratio of the bone particles to the water for injection is 1: 20.
In some embodiments, in step 5), the sodium hyaluronate gel concentration is 3% to 8%, for example: 3%, 4%, 5%, 6%, 7% or 8%.
In some embodiments, in step 5), the sodium hyaluronate gel is configured by: weighing 3-8 g of sodium hyaluronate, adding water for injection to 100g, stirring until the sodium hyaluronate is uniformly dispersed, sealing and standing at 2-8 ℃ for 3-16 h, and continuously stirring until the gel is transparent and has no visible particles.
Example 2
The present example provides a method for deproteinizing animal bone particles, comprising the steps of:
1) adding degreased animal bone particles into hydrogen peroxide, standing for 12-24h, removing hydrogen peroxide, placing in purified water, shaking and cleaning for 3-6 times, drying at 75-10 deg.C for 5-7h, and sieving with 14 mesh sieve to obtain sieved animal bone particles;
2) adding the sieved animal bone particles into an ethylenediamine solution, heating to slightly boil, keeping at the temperature of 100-125 ℃ for 7-9h, removing waste liquid, adding purified water, oscillating and cleaning for 3 times, and repeating the step twice;
3) cleaning the animal bone particles obtained in the step 2) in a closed container for 15 times by using purified water, cleaning for 2 times by using water for injection, wherein the cleaning process is 3-6 min/time, turning over the container during cleaning, and discarding waste liquid to obtain deproteinized bone particles.
In some embodiments, the mass ratio of the defatted bone particles to hydrogen peroxide in step 2) is 1 (2-4), for example, 1:2,1:3,1: 4; the mass ratio of the degreased bone particles to the purified water is 1 (2-4), for example, 1:2,1:3, and 1: 4.
In some embodiments, the concentration of the ethylenediamine solution in step 3) is 70% to 100%, e.g., 70%, 80%, 90%, 100%.
In some embodiments, the mass ratio of the sieved bone particles of step 3) to the ethylenediamine solution is 1 (2-6), for example, 1:2,1:3,1:4, 1:5, and 1: 6.
In some embodiments, the mass ratio of the bone particles to the purified water of step 4) is 1: 20; the mass ratio of the bone particles to the water for injection is 1: 20.
In some embodiments, the sodium hyaluronate gel concentration is between 3% and 8%, for example: 3%, 4%, 5%, 6%, 7% or 8%.
In some embodiments, the sodium hyaluronate gel is configured by: weighing 3-8 g of sodium hyaluronate, adding water for injection to 100g, stirring until the sodium hyaluronate is uniformly dispersed, sealing and standing at 2-8 ℃ for 3-16 h, and continuously stirring until the gel is transparent and has no visible particles.
Example 3
The embodiment provides a bone repair material, which is prepared from bovine femoral particles and 5% of sodium hyaluronate gel, wherein the mass ratio of the bovine femoral particles to the sodium hyaluronate gel is 10 (5-7), and in some embodiments, the mass ratio of the sodium hyaluronate gel is 10:5, 10:6 or 10: 7.
In some embodiments, the bovine femoral particle is a defatted, deproteinized bovine femoral particle.
In some embodiments, the degreasing process comprises the steps of: and (3) repeatedly and alternately oscillating and cleaning the ox femoral bone particles for 3-6 times by using isopropanol and purified water to obtain the degreased ox femoral bone particles.
In some embodiments, the deproteinization process comprises the steps of:
1) adding the degreased bone particles into hydrogen peroxide, standing for 12-24h, removing the hydrogen peroxide, placing in purified water, shaking and cleaning for 3-6 times, drying at 75-100 ℃ for 5-7h, and sieving with a 14-mesh sieve to obtain sieved bone particles;
2) adding the sieved bone particles into 70-100% ethylenediamine solution, heating to slightly boil, keeping at 125 ℃ for 7-9h, removing waste liquid, adding purified water, oscillating and cleaning for 3 times, and repeating the step twice;
3) washing the bone particles obtained in the step 2) with purified water for 15 times, washing with water for injection for 2 times, wherein the washing process is 3-6 min/time, turning over the container during the washing process, and discarding waste liquid to obtain deproteinized bone particles.
In some embodiments, the mass ratio of the animal bone particles to the isopropanol is 1 (2-3), e.g., 1:2,1: 2.5 or 1:3, and the mass ratio of the animal bone particles to the purified water is 1: 3.
in some embodiments, the mass ratio of the defatted bone particles to hydrogen peroxide in step 1) is 1 (2-4), for example, 1:2,1:3,1: 4; the mass ratio of the degreased bone particles to the purified water is 1 (2-4), for example, 1:2,1:3, and 1: 4.
In some embodiments, the mass ratio of the sieved bone particles of step 2) to the ethylenediamine solution is 1 (2-6), for example, 1:2,1:3,1:4, 1:5, and 1: 6.
In some embodiments, the mass ratio of the bone particles to the purified water of step 3) is 1: 20; the mass ratio of the bone particles to the water for injection is 1: 20.
In some embodiments, the sodium hyaluronate gel concentration is between 3% and 8%.
In some embodiments, the sodium hyaluronate gel is configured by: weighing 3-8 g of sodium hyaluronate, for example: 3g, 4g, 5g, 6g, 7g or 8g, adding water for injection to 100g, stirring until the sodium hyaluronate is uniformly dispersed, sealing and standing for 3-16 h at the temperature of 2-8 ℃, and continuously stirring until the gel is transparent and has no visible particles.
Example 4
The pore structure of the bone repair material (hereinafter referred to as "the product") prepared in example 1 was analyzed as follows: as shown in fig. 1A-1B, fig. 1A is an SEM image of the product magnified 50 times, fig. 1B is an SEM image of the product magnified 500 times, and it can be seen from fig. 1A-1B that sodium hyaluronate with a porous network structure is uniformly distributed on the surface of the bone repair material, which is beneficial to prolong the retention time of the bone repair material at the operation site and is beneficial to the proliferation, differentiation and migration of osteoblasts.
Meanwhile, the sodium hyaluronate has good hydrophilicity, so that the bone repair material has good plasticity. After three-dimensional reconstruction by Micro CT, see FIG. 2, bone morphological structural analysis was performed to obtain the bone volume fraction (BV/TV), the porosity being equal to 1-BV/TV × 100%. The porosity of the product was about 76.42 ± 8.52% as determined by analysis of 6 samples of about 5mm square. The porosity of the spongy bone is generally 70-80%, and the Micro CT analysis result of the porosity of the product meets the porosity requirement of the spongy bone. 3A-3B, the product maintains the trabecular bone and the through multistage pore space structure of natural bone, including macropores around the trabecular bone and mesopores on the trabecular bone, and is an interconnected pore structure. The size of the macropores is about 200-600 μm, and the size of the mesopores is about 50-100 μm. It is also seen that hydroxyapatite crystals exist finely in a weakly crystalline form, and that there are fine intergranular micropores, the micropore size being <1 μm. The weakly crystallized hydroxyapatite and the porous structure enable the product to have a high specific surface area, increase the contact area of the material with cells and body fluid, be more beneficial to the generation of new bones, and also enable new bone tissues to be fully contacted with the material.
Example 5
The total protein content of the product is measured as follows: taking a proper amount of sample, grinding, precisely weighing 1.0g, placing in a 10ml volumetric flask, wetting with 1ml of distilled water, gradually adding 25% phosphoric acid solution while shaking, assisting ultrasonic to accelerate sample dissolution, adding about 6ml of phosphoric acid solution to dissolve the sample, fixing the volume to a scale mark with distilled water, sucking 0.1ml, and placing in a test tube with a plug. The total protein content was < 0.1% (m/m) as determined by the Coomassie Brilliant blue method according to pharmacopoeia of the people's republic of China 2015 edition (0731).
Example 6
The influence of different forms of preparation methods on the compressive strength of the bone repair material is analyzed by taking a product A prepared from free sodium hyaluronate gel and inorganic bone particles, a product B prepared from cross-linked sodium hyaluronate gel and inorganic bone particles, a product C prepared from non-cross-linked sodium hyaluronate gel and inorganic bone particles after electrostatic spinning, and four groups of products, and the method is shown in figure 4. As can be seen from fig. 4, the compressive strength is lower after the pure unmodified sodium hyaluronate solution is mixed with the calcined inorganic bone particles; after the cross-linked sodium hyaluronate is mixed with the calcined inorganic bone particles, the compressive strength is improved, but the effect is limited; the unmodified sodium hyaluronate gel is subjected to electrostatic spinning treatment and then is mixed with calcined inorganic bone particles, and the microscopic nano structure is beneficial to improving the mechanical property of the material, but the material is in a gel state, so that the reinforcing effect is still poor; the product is prepared by the preparation method in the embodiment 1, has a three-dimensional reticular microscopic pore structure similar to a human bone, is beneficial to the adhesion of sodium hyaluronate gel, enhances the combination between an inorganic phase and an organic phase, and greatly improves the compressive strength.
Example 7
In the embodiment, a new zealand white rabbit skull limit defect model, an SD rat skull penetrability limit defect model and a canine alveolar bone defect repair model are used for observing the conditions of bone tissues, vascular ingrowth and bone density recovery of a defect part.
1. Test method
Taking 6 male New Zealand white rabbits with the weight of 2-2.5 kg; 6 SD rats with the weight of about 340-360 g; 6 adult dogs of 2-3 years old weigh 15.0-17.5 kg and are healthy. Are purchased from the laboratory animal center of the fourth military medical university of western and ann.
1) Rabbit skull penetrability defect model making and implantation experiment
24 male New Zealand white rabbits (2-2.5 kg) were anesthetized with 1% sodium pentobarbital at 35mg/kg, depilated at the top of the head with 8% sodium sulfide, washed, fixed on an operating table, and spread with a conventional disinfectant. At the parietal head, the skin was incised arcuately to the subperiosteal, exposing the frontal and parietal bones. Removing bones by using a small osteotome and a dental electric drill to form a circular full-layer bone defect area with the diameter of 15mm, reserving dura mater, and using a bone repair material which is implanted into the product after being washed by normal saline as an experimental group; the blank control group was not filled with any material and the periosteum and skin were sutured layer by layer. Penicillin is injected into muscle for 30min before operation and 20 ten thousand U immediately after operation. Animals were sacrificed at weeks 6, 12, and 24 after surgery, skull specimens were taken, decalcified, HE stained, and histologic microscopic observation was performed, and the material remaining rate and the new bone formation rate were analyzed by calculating the area using Image analysis software Image-Pro plus6.0, and the material remaining rate and the new bone formation rate were the area of the material or the area of the new bone divided by the total area of the analysis chart. The observation groups at 6 weeks, 12 weeks and 24 weeks of the material implantation group and the blank control 24 weeks of the observation group are 6 cases each.
2) SD rat skull penetrability defect model making and implantation experiment
6 SD rats with the weight of 340-360 g are prepared by preparing skins at the tops of the rats, anesthetizing animals by using 1% sodium pentobarbital according to the volume of 30mg/kg, making arc-shaped incisions on the skins at the tops of the heads under aseptic conditions, peeling off and exposing the skull, removing bones by using a small osteotome and a dental electric drill to form 2 left and right adjacent round full-layer bone defect areas with the diameter of 3mm, reserving dura mater, washing by using normal saline, selecting the right defect area to implant the middle bone repair material in the product, making blank control on the left bone defect area, and suturing the incisions. At week 8 after surgery, the animals were sacrificed and skull specimens were taken for Micro CT bone density detection and histological observation.
3) Canine alveolar bone defect repair model and implantation experiment
The right side of the mandible of 6 adult dogs is taken as an experimental side, the left side of the mandible is taken as a control side, and alveolar bone defect models are respectively established:
grinding with a high-speed turbine dental drill to obtain bone defect regions with diameter of 8mm and depth of 6mm, wherein 4 dog bone defect regions are located at the interval of 4 th premolar and 1 st molar alveolus of lower jaw, and 2 dog bone defect regions are located at the root bifurcation of 1 st molar of lower jaw. The bone repair material is implanted into the experimental side, is in the form of scattered particles, is not pressurized, is parallel to the bone surface, is covered with a biological membrane and is sutured; the control side was not implanted with any material. Animals were sacrificed 8 weeks after the postoperative routine feeding. The healing conditions of the alveolar bone at the experimental side and the control side are observed and recorded through a general specimen, and the pathological specimen is taken for optical microscopy.
2. Results of the experiment
1) Rabbit skull defect repair
Experimental groups: at week 6 post-surgery, a large amount of new bone was formed around the bone repair material particles. At 12 weeks after surgery, new bone in the bone defect area has reached the central area, partially connected into pieces, and reformed into lamellar bone, and the bone repair material particles are mostly surrounded by new bone. The maturity of new bone is further improved at 24 weeks after surgery, as shown in fig. 5A, 5B, 5C. Blank control group: at 24 weeks post-surgery, most of the defect area was still fibrous connective tissue, see fig. 5D. At 6 weeks after operation, the new bone formation rate is about 13.27%, and the material residual rate is about 27.45%; at 12 weeks after operation, the new bone generation rate is about 26.73%, and the material residual rate is about 24.62%; at 24 weeks after surgery, the new bone formation rate was about 35.54%, and the material remaining rate was about 19.83%, as shown in Table 1. By calculating the area of the new bone and the area of the residual material, it can be seen that the new bone generation is gradually increased along with the extension of the repair time, and the bone grafting material is slowly degraded.
Table 1 new osteogenesis rate and material remaining rate (%, n = 6) of experimental group
Time | Rate of new bone formation | Residual rate of |
6 weeks | 13.27±3.68 | 27.45±5.39 |
For 12 weeks | 26.73±5.22 | 24.62±4.34 |
24 weeks | 35.54±4.85 | 19.83±5.17 |
2) SD rat skull defect repair
SD rats with skull defect repair test for 8 weeks, Micro CT observation shows that the bone defect area has healed, while the control group (unrepaired group) has no bone healing, as shown in figure 6. After 8 weeks, the bone density of the bone repair area and the surrounding normal bone is analyzed by pixel CT value by using Micro CT, the difference between the two is compared, and the detection result is shown in figure 7. Bone density in the 8-week post-operative repair area was nearly close to that of normal bone, with no significant difference between the two groups (F-test, P > 0.05). The bone regeneration state of the experimental group and the control group was observed by HE staining for 8 weeks after the operation, and the results showed that, as shown in fig. 8A-8B, the new bone mass of the experimental group was significantly greater than that of the control group, and due to individual differences, the new bone mass between the experimental groups was also significantly different, and no significant new bone formation occurred in the control group.
3) Canine alveolar bone defect repair
The soft tissues of 6 dogs are well healed, the gum color, the shape and the quality are normal, and the inflammatory reactions such as congestion, swelling, erosion and the like are not seen.
Alveolar bone healing, see figures 9A-9B. There was no significant difference in healing of alveolar bone defects at various sites. The alveolar bone surface of the bone repair material filling set in the product is flat, and the bone regeneration is good. Through histological section observation, the bone wall of the filling group of the product is equivalent to the normal side, the bone density is higher, the bone tissue of the unrepaired group is regenerated, but the height of the bone wall is lower than that of the normal side, the bone gaps are more, and the bone density is low. Meanwhile, at 8 weeks, biofilm residues were still found on the defect tops of the experimental and control groups, and there was no significant fibrous connective tissue ingrowth into the alveolar bone defect area in the experimental group, as shown in fig. 10A. In contrast, the control group had significant fibrous tissue growth into the defect area, as shown in FIG. 10B.
Example 8
This example is a study of the healing effect of bone repair materials on tooth extraction wounds. The absorption of local alveolar bone often takes place among the in-process of the healing of tooth extraction wound rebuild after the tooth extraction operation, leads to alveolar bone height to reduce, and the thickness attenuation to influence later stage artificial tooth and repair, be more unfavorable for the planting body and implant. To solve such problems, a vestibular deepening operation or an alveolar bone heightening operation is often required to obtain a necessary alveolar bone profile. However, these surgical methods are very traumatic, increase the pain of the patient, and are all remedial measures taken after alveolar bone atrophy, and the effect is often unsatisfactory. Therefore, how to promote the healing of the tooth extraction wound and reduce the alveolar bone resorption after tooth loss is one of the important problems in the current oral and maxillofacial surgery research. Some methods for preventing alveolar bone resorption appear at home and abroad in recent years, but the methods are difficult to popularize and apply clinically due to the respective defects. The ideal healing state of the tooth extraction socket is that the bone defect formed after tooth extraction is completely filled with new bone, and the surface of the wound is completely sealed by soft tissue mucosa. The bone graft material filled after tooth extraction is beneficial to the reconstruction of alveolar bone and has important significance for the stability of later-stage implants. The experiment detects the effect of the product on alveolar bone retention by filling the dental extraction socket with single-wall bone defects after tooth extraction with the product.
1. Test method
6 adult domestic dogs of 2-3 years old weigh 15.0-17.5 kg and are healthy. Purchased from the laboratory animal center of western-style medical university, fourth military. The right side of the mandible of 6 adult dogs is taken as an experimental side, the left side of the mandible is taken as a control side, and the bilateral symmetry molar is respectively pulled out. Implanting the bone repairing material into the product at experimental side, and covering with biological membrane without pressurizing to make the bone repairing material flush with bone surface; the control side was not implanted with any material and was covered with a biofilm and sutured. Animals were sacrificed 8 weeks after the postoperative routine feeding. The healing conditions of alveolar bones on the experimental side and the control side are observed and recorded through a general specimen, a pathological specimen is taken for optical microscopy, the difference of the bone mass and the thickness of a trabecula bone between two experimental groups is compared through Micro CT, and the tissue morphology is observed through histological sections. And simultaneously, blood is drawn at 2 weeks, 4 weeks and 8 weeks after the operation, and the calcium and blood phosphorus detection is carried out to investigate whether the material can cause the change of the calcium and phosphorus metabolism level of the animals.
2. Results
At 8 weeks after operation, the soft tissues at the tooth extraction positions of the two groups are well covered, and no inflammatory reaction such as congestion, swelling, erosion and the like is seen. Experimental groups: BV/TV% =81.99 +/-3.12, trabecular bone thickness is 0.492mm +/-0.033 mm. Blank control group: BV/TV% =63.44 ± 3.34, trabecular bone thickness 0.251mm ± 0.061mm, see fig. 11A-11B. The histological observation results show that the formation amount of new bones at the blank group defect is small, soft tissues are taken as main materials, the bone repair degree of the experimental group is very good, and the new bones are continuously fused together, which is shown in fig. 12A and 12B.
Example 9 study of cellular compatibility
In the process of repairing bone defects by the product, normal attachment, growth and proliferation of cells with osteogenesis capacity on the surface of the product are key steps for successfully repairing the bone defects, so whether the product can provide a proper space structure for the cells to grow for seed cells is an important index for evaluating whether the material can be used as a bone repair material, and therefore, the biocompatibility of the material at a cell level is evaluated by observing the attachment and proliferation conditions of bone marrow mesenchymal cells on the surface of the product in vitro and the cell state of fibroblasts and the product in co-culture.
1. Test method
1) Adhesion research of SD rat bone marrow mesenchymal cells on surface of product
Aseptically taking down double lower limbs from a super clean bench, shearing off fur, placing in a dish containing 75% ethanol, replacing instruments and the super clean bench, removing muscle tissues around thighbone and shinbone, and repeatedly washing with phosphate buffer solution. Cutting off two ends of the backbone, exposing the marrow cavity, puncturing the bone ends at two sides with a No. 7 needle, and extracting 4ml of DMEM medium containing 10% fetal calf serum by volume fraction with a 5ml syringe to wash out the marrow. Centrifuge at 800 rpm for 5 minutes, resuspend the pellet using α -MEM medium, centrifuge again at 800 rpm for 5 minutes. Blowing, sieving, centrifuging, and re-suspending and precipitating in alpha-MEM culture solution. Culturing at 37 deg.C in 5% CO2 incubator, changing liquid once for 4 hr, and washing off non-adherent cells. Culturing at 37 deg.C in 5% CO2 incubator, and changing the culture solution once after 1-2 d. Inoculating the 3 rd generation mesenchymal cells on the surface of the product, adding alpha-MEM culture solution, and culturing at 37 ℃ in a 5% CO2 incubator. After 24 hours, the product inoculated with cells was fixed with 3% glutaraldehyde, and after lyophilization, the growth of the cells was observed by scanning electron microscopy.
2) Research on proliferation capacity of bone marrow mesenchymal cells on product
Aseptically taking down double lower limbs from a super clean bench, shearing off coat, placing in a dish containing 75% ethanol, replacing instruments and the super clean bench, removing muscle tissues around thighbone and shinbone, and repeatedly washing with phosphate buffer solution. Cutting off two ends of the backbone, exposing the marrow cavity, puncturing the bone ends at two sides with a No. 7 needle, and extracting 4ml of DMEM medium containing 10% fetal calf serum by volume fraction with a 5ml syringe to wash out the marrow. Centrifuge at 800 rpm for 5 minutes, resuspend the pellet using α -MEM medium, centrifuge again at 800 rpm for 5 minutes. Blowing, sieving, centrifuging, and re-suspending and precipitating in alpha-MEM culture solution. Culturing at 37 deg.C in 5% CO2 incubator, changing liquid once for 4 hr, and washing off non-adherent cells. Culturing at 37 deg.C in 5% CO2 incubator, and changing the culture solution once every 1-2 days.
Inoculating the 3 rd generation bone marrow mesenchymal cells on the surface of the product and the synthetic hydroxyapatite biological ceramic, adding alpha-MEM culture solution, and culturing in a 5% CO2 incubator at 37 ℃. The number of cells was measured every 24 hours on days 1 to 5 using MTT, and a cell growth curve was plotted.
3) Research on co-culture of fibroblasts and the product
Inoculating human fibroblast to 6-well plate, and putting 3-5 granules of the product into the well plate. The cell state and extracellular matrix formation of the contact surface between the product particles and the surrounding cells were observed at 0, 24, 48, and 96 hours, respectively.
Results
Bone marrow mesenchymal cells were inoculated to the product, and after 24 hours, scanning electron microscopy showed that the cells were all adhered to the scaffold material, indicating that the bone marrow mesenchymal cells were in good extension state, as shown in fig. 13A. The proliferation of bone marrow mesenchymal cells on the product and synthetic hydroxyapatite, the MTT dye method detects the change of the cell number of the bone marrow mesenchymal cells in 1-5 days, reflects the proliferation of the cells on the surfaces of the two materials, and refers to FIG. 13B.
In the experiment, in order to observe the affinity of the product to the mesenchymal cells, the mesenchymal cells are directly inoculated on the surface of the product for in vitro culture, and the scanning electron microscope result shows that the cells can be adhered and grow on the surface of the material and have good growth state. The proliferation conditions of the mesenchymal cells on the surface of the product and the surface of the synthesized hydroxyapatite are compared through measuring the cell number for 1 to 5 days, and the result shows that the adhesion efficiency and the proliferation efficiency of the cells on the surface of the bone induction calcined bone are higher than those of the synthesized hydroxyapatite material. The product has no influence on the normal metabolic process of cells and has good cell compatibility.
The experimental result shows that the prepared product has excellent cell compatibility, can provide a substrate for mesenchymal growth of bone marrow, is beneficial to the adhesion and growth of osteoblasts, and has good cell state and sufficient extracellular matrix secretion in co-culture with human fibroblasts. The product has good cell compatibility.
EXAMPLE 10 histocompatibility study
1) Experimental methods
SD rats 10 (5 weeks old, male and female unlimited) were anesthetized by intramuscular injection into the legs with 1% sodium pentobarbital 35mg/kg body weight, and were fixed on the operating table in the prone position. Preparing skin on both sides of back, sterilizing with iodophor, and spreading towel. Two sides of the back, chest and waist spine are respectively provided with 2 incisions, subcutaneous tissues are separated in a blunt manner, and 4 subcutaneous lacunae are formed, wherein the transverse spacing is 2cm, and the longitudinal spacing is 2 cm. The product material is implanted and the subcutaneous and cutaneous sutures are layered. The artificial feed is wrapped without pressure and fed, and the penicillin is 40 ten thousand units/day after the operation for 3 days and is injected intramuscularly. Taking 4 pieces of material respectively 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks after operation, fixing with formalin, decalcifying for 48h, washing with running water for 24h, embedding the section with normal paraffin, and performing HE staining observation.
2) Results
General observation: the materials of the 2-week group are accessible in vitro, the outline is clear, the materials are wrapped by surrounding tissues, the fibrous membrane is thin, the tissue blocks obtained are loose in structure and are easy to separate from the materials. The material can still be touched in vitro after 4 weeks, the fibrous membrane formed by surrounding tissue is thicker, and fibrous connective tissue can grow into the pores of the material after stripping. 6. The material is tightly combined with the surrounding tissue in 8 weeks, the material is in a block shape and has higher hardness, and the interface of the material and the surrounding tissue begins to have fine depressions. A large number of microvessels are formed around the 12-week material, and the material is tightly attached to the surrounding tissue. The tissues around each group of materials have no necrosis or abscess. Histological examination: as shown in fig. 14A-14E, the tissue mass formed by the 2 week group material and the surrounding tissue was loose with fibroblast proliferation and inflammatory cell infiltration dominated by neutrophils, lymphocytes and plasma cells. The 4-week group implanted material has loose connective tissue growing in, and the tissue block formed by the material and the surrounding tissue is more compact than the 2-week group, and still mainly infiltrates with neutrophils and lymphocytes. The number of inflammatory cells is obviously reduced at 6 weeks, the materials in the 8-week group have good biocompatibility with surrounding tissues, no obvious inflammatory cells exist, and blood vessels are formed around the materials. The material in the 12-week group has a degradation tendency, a plurality of blood vessels are formed around the material, fibroblasts grow around the material, and inflammatory cells are not found. Tissue degeneration and necrosis were not observed in any of the groups.
3) Conclusion
In the experiment, the product is buried under the skin of an SD rat, the histocompatibility of the SD rat is detected, and the observation period is up to 12 weeks. The product implanted under the skin has no foreign body rejection reaction. In the early stage of implantation, there was neutrophil and lymphocyte infiltration due to acute inflammatory response of the wound, but with time the number of inflammatory cells decreased significantly and good biocompatibility was achieved at 6 weeks. The product has better tissue compatibility.
Therefore, the product has no immunogenicity, good histocompatibility and can be integrated by organism tissues, and the loose porous structure of the material can guide the formation of new blood vessels and sufficiently support the regeneration and reconstruction of new bone tissues.
Claims (10)
1. The bone repair material is characterized by being prepared by mixing bovine femoral particles and sodium hyaluronate gel, wherein the mass ratio of the bovine femoral particles to the sodium hyaluronate gel is 10: 5-7.
2. The bone repair material of claim 1, wherein the bovine femoral particle is a defatted, deproteinized bovine femoral particle.
3. Bone repair material according to claim 1, characterized in that said degreasing process comprises the following steps: and (3) repeatedly and alternately oscillating and cleaning the ox femoral bone particles for 3-6 times by using isopropanol and purified water to obtain the degreased ox femoral bone particles.
4. The bone repair material according to claim 1, wherein the deproteinization process comprises the steps of:
adding the degreased bone particles into hydrogen peroxide, standing for 12-24h, removing the hydrogen peroxide, placing in purified water, shaking and cleaning for 3-6 times, drying at 75-100 ℃ for 5-7h, and sieving with a 14-mesh sieve to obtain sieved bone particles;
adding the sieved bone particles into an ethylenediamine solution, heating to slightly boil, keeping at the temperature of 100-125 ℃ for 7-9h, removing waste liquid, adding purified water, oscillating and cleaning for 3 times, and repeating the step twice;
washing the bone particles obtained in the step 2) with purified water for 15 times, washing with water for injection for 2 times, wherein the washing process is 3-6 min/time, turning over the container during the washing process, and discarding waste liquid to obtain deproteinized bone particles.
5. The bone repair material according to claim 3, wherein the mass ratio of the bovine femoral particles to the isopropanol is 1 (2-3), and the mass ratio of the bovine femoral particles to the purified water is 1: 3.
6. the bone repair material according to claim 4, wherein in the step 1), the mass ratio of the degreased bone particles to the hydrogen peroxide is 1 (2-4); the mass ratio of the degreased bone particles to the purified water is 1 (2-4).
7. The bone repair material according to claim 4, wherein the concentration of the ethylenediamine solution in step 2) is 70% to 100%.
8. The bone repair material according to claim 4, wherein in the step 2), the mass ratio of the sieved bone particles to the ethylenediamine solution is 1 (2-6).
9. The bone repair material according to claim 4, wherein in step 3), the mass ratio of the bone particles to the purified water is 1: 20; the mass ratio of the bone particles to the water for injection is 1: 20.
10. The bone repair material of claim 1, wherein the sodium hyaluronate gel is at a concentration of 3% to 8% and is formulated by: weighing 3-8 g of sodium hyaluronate, adding water for injection to 100g, stirring until the sodium hyaluronate is uniformly dispersed, sealing and standing at 2-8 ℃ for 3-16 h, and continuously stirring until the gel is transparent and has no visible particles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011545415.9A CN112587729B (en) | 2020-12-24 | 2020-12-24 | Bone repair material |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011545415.9A CN112587729B (en) | 2020-12-24 | 2020-12-24 | Bone repair material |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112587729A true CN112587729A (en) | 2021-04-02 |
CN112587729B CN112587729B (en) | 2023-05-09 |
Family
ID=75200662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011545415.9A Active CN112587729B (en) | 2020-12-24 | 2020-12-24 | Bone repair material |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112587729B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113750293A (en) * | 2021-10-15 | 2021-12-07 | 青岛蓝皓生物技术有限公司 | Preparation method of bone repair material |
CN113842502A (en) * | 2021-09-29 | 2021-12-28 | 西安德诺海思医疗科技有限公司 | Injection filler containing deproteinized bone and preparation method thereof |
CN114949360A (en) * | 2021-10-26 | 2022-08-30 | 深圳市迈捷生命科学有限公司 | Injectable bone induction repair material and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101020082A (en) * | 2007-03-09 | 2007-08-22 | 高心 | Bone repairing material and its prepn process and use |
CN103638557A (en) * | 2013-10-24 | 2014-03-19 | 陕西佰傲再生医学有限公司 | Antigen-removing biological bone and preparation method thereof |
CN105126169A (en) * | 2015-07-10 | 2015-12-09 | 蒋青 | Allograft bone meal as well as preparation method and application thereof |
CN110917393A (en) * | 2019-12-30 | 2020-03-27 | 江阴金泰克生物技术有限公司 | Bone meal gel and preparation method thereof |
CN112023120A (en) * | 2020-09-10 | 2020-12-04 | 湖北联结生物材料有限公司 | Injectable pre-filled bone repair particle and preparation method and application thereof |
-
2020
- 2020-12-24 CN CN202011545415.9A patent/CN112587729B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101020082A (en) * | 2007-03-09 | 2007-08-22 | 高心 | Bone repairing material and its prepn process and use |
CN103638557A (en) * | 2013-10-24 | 2014-03-19 | 陕西佰傲再生医学有限公司 | Antigen-removing biological bone and preparation method thereof |
CN105126169A (en) * | 2015-07-10 | 2015-12-09 | 蒋青 | Allograft bone meal as well as preparation method and application thereof |
CN110917393A (en) * | 2019-12-30 | 2020-03-27 | 江阴金泰克生物技术有限公司 | Bone meal gel and preparation method thereof |
CN112023120A (en) * | 2020-09-10 | 2020-12-04 | 湖北联结生物材料有限公司 | Injectable pre-filled bone repair particle and preparation method and application thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113842502A (en) * | 2021-09-29 | 2021-12-28 | 西安德诺海思医疗科技有限公司 | Injection filler containing deproteinized bone and preparation method thereof |
CN113750293A (en) * | 2021-10-15 | 2021-12-07 | 青岛蓝皓生物技术有限公司 | Preparation method of bone repair material |
CN114949360A (en) * | 2021-10-26 | 2022-08-30 | 深圳市迈捷生命科学有限公司 | Injectable bone induction repair material and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112587729B (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shayesteh et al. | Sinus augmentation using human mesenchymal stem cells loaded into a β-tricalcium phosphate/hydroxyapatite scaffold | |
JP5408578B2 (en) | Composition for autologous or allogeneic transplantation using dental pulp stem cells and use thereof | |
Wang et al. | Hybrid composites of mesenchymal stem cell sheets, hydroxyapatite, and platelet‑rich fibrin granules for bone regeneration in a rabbit calvarial critical‑size defect model | |
CN101564553B (en) | Humanization active forging bone and preparation method thereof | |
CN101020082B (en) | Bone repairing material and its prepn process and use | |
CN1265845C (en) | Tissue regenerating base material, implanting material and method of producing the same | |
Zhang et al. | 3D-printed pre-tapped-hole scaffolds facilitate one-step surgery of predictable alveolar bone augmentation and simultaneous dental implantation | |
CN112587729B (en) | Bone repair material | |
CN109954167B (en) | Bone repair material and application thereof | |
EP1900809A1 (en) | Method of preparing cell for bone tissue formation and application of cell for bone tissue formation | |
JPWO2002040071A1 (en) | Composition for forming bone or periodontal tissue, and injection for forming bone or periodontal tissue | |
CN110384826B (en) | A kind of oral guided bone regeneration membrane prepared from amniotic periosteal acellular matrix and preparation method thereof | |
Cheng et al. | A novel animal model treated with tooth extraction to repair the full-thickness defects in the mandible of rabbits | |
CN1668732A (en) | Treatments with autologous fibroblast | |
CN101269241A (en) | A kind of calcium sulfate composite bone repair material and its preparation method and application | |
CN110585484A (en) | Composite bone powder for bone tissue and preparation method and application thereof | |
CN112618798B (en) | A kind of preparation method of bone repair material | |
CN101564555A (en) | Tissue engineering bone implant and method for constructing the same | |
Tibeică et al. | Bone regeneration influence in the success of periimplant surgery | |
Wang et al. | Study of a new nano-hydroxyapatite/basic fibroblast growth factor composite promoting periodontal tissue regeneration | |
CN112076349A (en) | Tissue engineering alveolar bone tissue and preparation method thereof | |
Unnikrishnan et al. | Nanocomposite fibrous scaffold mediated mandible reconstruction and dental rehabilitation: An experimental study in pig model | |
CN2824875Y (en) | An injection type tissue engineering bone engraft | |
CN102123744B (en) | Biomaterials containing calcium phosphate | |
Mangano et al. | Combining scaffolds and osteogenic cells in regenerative bone surgery: a preliminary histological report in human maxillary sinus augmentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |